The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Chikungunya Arthritis

Chikungunya Arthritis

March 28, 2018 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In this review, the authors address the key pathophysiologic mechanisms that drive acute and chronic chikungunya arthritis, arguably the most incapacitating sequela among long-lasting chikungunya virus disease manifestations, based on recent animal experimental disease models and epidemiologic studies. They explore the latest findings in therapeutic development aimed at limiting viral spread and at immune and inflammatory mechanisms, and address the implications of such findings in current and future clinical care of chikungunya virus patients.

You Might Also Like
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
  • Chikungunya Fever May Trigger Chronic Articular Symptoms
  • Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis

Chikungunya virus, a previously neglected tropical arthritogenic alphaviral infection, gained global significance in the past decade after a series of devastating outbreaks exposed its severe public health and economic impact, as well as the significant risk of acquired disabilities incurred by international travelers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although developed economies that have experienced significant numbers of traveler-imported cases are somewhat equipped to manage the chikungunya virus disease burden, less economically developed regions of the world—in particular densely populated urban areas—where epidemics have become most resilient, have seen their public health systems overwhelmed by the disease.

Chikungunya virus is recognized as an emerging biphasic disease, described as an acute infection followed by persistent symptoms. Experts have defined three successive clinical stages. In symptomatic, infected individuals, the first stage encompasses an acute incapacitating febrile viremic phase together with residual symptoms. The two final stages are characterized by persistent manifestations: a post-acute stage (from 21 days after the onset of infection to the end of the third month) and a chronic stage (beyond three months). Schematically, the disease progresses to resolution without sequelae either spontaneously or after treatment, or to a persistence of articular and general symptoms, or to aggravation due to an inflammatory or degenerative process.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Symptoms include a range of acute manifestations, among which fever, severe joint and muscle pain, headache and rashes are prominent. Concern is mounting over the persistence of long-lasting manifestations associated with debilitating effects of the disease and the deterioration of overall health and quality of life. Among these, chronic arthralgia/arthritis (joint pain/joint stiffness plus joint swelling, respectively), musculoskeletal injury and fatigue—and to a lesser extent, neurocognitive and sensorineural manifestations—have been shown to contribute significantly to the economic burden of the disease.

Although vaccines have reached human trials and a range of potential antiviral compounds have undergone preclinical evaluation, no licensed vaccines or antiviral therapies are available. Both acute and chronic disease manifestations are of significant concern, and there are currently no specific, approved drugs to treat either form of the disease.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis, chikungunya, contracted chikungunya virus

You Might Also Like:
  • Experimental Drug Combination Curbs Chikungunya Arthritis in Mice
  • Chikungunya Fever May Trigger Chronic Articular Symptoms
  • Mosquito-Borne Chikungunya Virus Can Cause Long-Term Arthritis
  • Cytokine Response Provides Clues to Chikungunya Sequelae

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.